Diligence memo · auto-generated · as of July 2, 2026
TIXiMED, Inc.
TIXiMED, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
TIXiMED, Inc. operates in Pharmaceuticals, based in BIRMINGHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
TIXiMED, Inc. has raised $550K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $550K on 2024-10-15.
Most recent recorded round closed around 2024-10-15.
Valuation (modeled)modeled
Provath models TIXiMED, Inc. at approximately $2.1M (range $308K–$6.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.82× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era. Within the normal band (82% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 21 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 13% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 4% of those peers.
Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.